Cookies show us what works. Privacy
Cookies show us what works. Privacy
22 funds hold it · Insiders net selling
No insider open-market trades in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 9, 2026
Period ending
Sep 30, 2026
Earnings per share
-$3.63 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Nov 15, 2026
EPS expected
-$5.60 to -$2.74
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 9, 2026 | -$3.23est. -$3.63 | +11.13%beat | $0.00Alpha Vantage | No year-ago quarter |
| Jun 30, 2026Reported Aug 6, 2026 | -$2.87est. -$3.60 | +20.28%beat | $0.00Alpha Vantage | No year-ago quarter |
| Mar 31, 2026Reported May 7, 2026 | -$3.20est. -$3.68 | +13.01%beat | $0.00Alpha Vantage | No year-ago quarter |
| Dec 31, 2025Reported Feb 19, 2026 | -$3.50est. -$3.13 | -11.82%miss | $0.00Alpha Vantage | -100.0%from $7.5M |
| Sep 30, 2025Reported Nov 5, 2025 | -$3.36est. -$3.49 | +3.72%beat | $0.00SEC filing | -100.0%from $302.0K |
| Jun 30, 2025Reported Aug 4, 2025 | -$3.31est. -$3.36 | +1.49%beat | $0.00SEC filing | -100.0%from $357.0K |
| Mar 31, 2025Reported May 2, 2025 | -$3.29est. -$3.21 | -2.49%miss | $0.00SEC filing | -100.0%from $431.0K |
| Dec 31, 2024Reported Feb 28, 2025 | -$2.94est. -$2.82 | -4.29%miss | $7.5MAlpha Vantage | +1349.1%from $515.0K |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | $77.5M | $39.0K | — | — |
| Gross profit | -$77.5M | -$39.0K | — | — |
| What it spent | ||||
| Research and development | $77.5M | $78.0M | $69.4M | $64.2M |
| Sales and admin | $19.5M | $27.9M | $27.5M | $42.7M |
| Other operating costs | -$77.5M | — | — | — |
| Total operating expenses | $19.5M | $105.9M | $96.9M | $106.9M |
| What was left | ||||
| Operating profit | -$97.0M | -$105.9M | -$96.9M | -$106.9M |
| Profit before tax | -$88.9M | -$92.6M | -$83.7M | -$94.2M |
| Net profit | -$88.9M | -$92.6M | -$83.7M | -$94.2M |
| EBITDA | -$88.9M | -$92.5M | -$83.7M | -$94.2M |
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Wells Fargo Upgrades Praxis Precision Medicines(PRAX.US) to Buy Rating, Raises Target Price to $509
BullishNov 17Praxis Precision Medicines upgraded by Wells Fargo with a new price target
BullishNov 17Wells Fargo upgrades Praxis Precision Medicines stock rating on endpoint confidence
BullishNov 17Two investors report 1.36M Praxis Precision Medicines (PRAX) shares but disclaim group status.
NeutralNov 16Guggenheim raises Praxis Precision Medicines price target to $1,050 By Investing.com
BullishNov 16Baird Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $568
BullishNov 16Praxis Precision Medicines rated Strong Buy with $601 fair value, FDA decision on key drug in January is pivotal.
BullishNov 16RBC Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $478
BullishNov 1312 macro signals shaping PRAX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results